Hepatocellular Carcinoma CPG Update v1.1(A) Now Available

By SITC Scientific Publications News posted 09-01-2023 00:00

  

In accordance with the Institute of Medicine’s Standards for Developing Trustworthy Clinical Practice Guidelines (CPGs), SITC CPGs undergo periodic evaluation to assess if new evidence necessitates modifications to recommendations, treatment algorithms, or other guideline content. This is done through our “SITC Living Guidelines” rapid update protocols designed to ensure SITC’s CPGs are up-to-date with cutting-edge thinking and incorporate the leading expert guidance in cancer immunotherapy care – a vital service to treating clinicians and those along the whole cancer care continuum. 

Rapid Update v1.1(A) Summary
The information below provides an overview of update v1.1(A) to the "Society for the Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma" published in Journal for ImmunoTherapy of Cancer (JITC).  

  • On October 21, 2022, the United States Food and Drug Administration approved tremelimumab in combination with durvalumab for adult patients with unresectable HCC. Approval was based on statistically significant and clinically meaningful improvement in overall survival for tremelimumab plus durvalumab compared to sorafenib in the phase III HIMALAYA trial, which enrolled patients with confirmed unresectable HCC who had not received prior systemic treatment. In light of this approval, narrative text and recommendations within the guideline were updated via an addendum. Additionally, a new treatment algorithm was developed.

How to View the Living Guideline Rapid Update

Through the use of an innovative technology, rapid updates are swiftly integrated into our existing published guidelines in a clear and concise manner. An overlay system highlights affected content and provides new text reflecting the updated Expert Panel guidance as well as important supporting information, data, and references, as applicable. These rapid updates show the progression of the changes by using a version numbering system that accompanies each new posted update.

  • View Update v1.1(A) as an addendum to the original publication in JITC

For More Information

  • SITC Hepatocellular Carcinoma Cancer CPG  – Overview of all available updates and companion guideline educational offerings for this guideline
  •         SITC Guidelines Program – Listing of all published guidelines in the SITC CPG catalogue and more about the SITC Living Guidelines rapid updates
  •         Follow us on social media – #SITCGuidelines on “X” and LinkedIn
  •          Questions – Contact a member of the SITC guideline development staff at scientificresources@sitcancer.org

0 comments
3 views

Permalink